What happened to the ARDX analyst rating on March 12, 2026?

Leerink Partners maintained an **Outperform** on Ardelyx, Inc. (ARDX) on **March 12, 2026**. The note was confirmatory after a company conference and did not include a new price target.

Does the maintained Outperform mean a price target changed for ARDX?

No. The StreetInsider summary shows no new price target and reports **0.0% ($0.0)** price change at release. The note reiterated confidence without updating numeric targets.

How should investors interpret the maintained ARDX rating?

A maintained Outperform signals continued analyst confidence but no new catalyst. Investors should combine this ARDX analyst rating with financials, upcoming milestones, and Meyka AI insights before making decisions.

What is Meyka AI’s current grade for ARDX?

Meyka AI rates **ARDX with a grade of B+**, based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. This is informational and not investment advice.

Analyst Ratings

Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026

ByHuzaifa Zahoor March 13, 2026March 13, 2026

Leerink Partners on March 12, 2026 maintained an Outperform on Ardelyx, Inc. (ARDX), marking the latest public ARDX analyst rating after the firm’s post-conference review. The note left the rating unchanged and reported no price action at time of release. This maintained stance gives investors a clear read on analyst conviction from a notable healthcare specialist. Meyka AI reviewed the note and the market context to show what this ARDX analyst rating means for investors and trading downside or upside given Ardelyx’s current market cap of $1,388,098,020.